Kirsteen Maclean (Moderator)
Director of Biomarker and Translational Strategy, Ultivue
Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors but is challenging in that only a minority of patients respond. Therapies that rely on immune activation, such as checkpoint inhibitors, have been shown to be especially difficult due to the complex and heterogeneous immune escape mechanisms which can develop in each patient. Therefore, development of robust biomarkers coupled with spatial analysis of tissue is key for enabling rational patient selection and the design of precise combination therapies.
The use of multiplex immunohistochemistry/immunofluorescence (mIHC/IF) provides much needed insight into cellular composition, cellular functions, and cell-cell interactions. Importantly, recent studies have used mIHC/IF to explore specific immune cells as part of the tumor immune microenvironment (TME) and found that it is helpful for clinical prognosis and efficacy prediction in patients with cancer.
In this presentation we will highlight a streamlined unique digital pathology workflow supporting whole slide imaging of a high-plex mIF and traditional H&E fusion on a single tissue slide for a comprehensive tissue immunophenotyping analysis.
Date: 15 June 2021 (Tuesday)
Time: New York 10:00 | London 15:00 | Paris 16:00 | Singapore 22:00 | Tokyo 23:00 | Sydney 00:00 (16 June)
Duration: 90 minutes
Event structure: 30-min presentation + 30-min discussion + 30-min Q&A
Registration fee: Complimentary access
Webinar on-demand: Available to view until midnight 2 July 2021 (registration is required)
Kirsteen Maclean PhD (Moderator)
Director of Biomarker and Translational Strategy – Ultivue
Kirsty has 20 years of leadership experience addressing academic, clinical, biotechnology, clinical research organizations (CRO) and pharmaceutical industries through clinical/technical communication, sales support, and market intelligence. Most recently, Kirsty was instrumental in overseeing commercial applications for CodexDNA enabling rapid antibody development for vaccines and novel therapeutics using an automated cloning platform. Previously Kirsty held leadership roles in commercial development and scientific communications at Definiens (now part of AstraZeneca), Nanostring Technologies and ThermoFisher Scientific.She holds a PhD in Hematology and a BS (hons) in Biochemistry.
Florian Leiss PhD
VP Digital Health Strategies – Ultivue
Florian Leiss is VP Digital Health Strategies at Ultivue. He is responsible for digital and data-driven offerings and image analysis. Florian has been working for the 10+ years in software development for healthcare to make AI-powered CDx in oncology a reality, to support radiologists with routine reporting, or to empower pathologists with image analysis at AstraZeneca, Smart Reporting and Definiens. He holds PhDs in neuroscience and philosophy.
Keith Wharton, MD PhD FCAP
Vice President, Medical Director – Ultivue
Keith is a board-certified human anatomic pathologist leading Ultivue’s Pathology and Biomarker Analytics team, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine.
Mark Rees PhD
Vice President, Corporate Development – Ultivue
Mark Rees, PhD joined Ultivue’s executive team in January as Vice President of Corporate Development. Mark has 21+ years of leadership experience in Scientific Affairs and Business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher) and Novocastra Laboratories. He holds a PhD in Molecular Biology & Microbiology, MS in Industrial Microbiology and a BS (hons) in Biochemistry, graduating from Newcastle University Medical School, England UK.
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration of tissue samples for precision medicine research by integrating a unique approach that combines multiplex biomarker analysis with same slide traditional H&E. These highly customizable solutions and scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
With over a decade of experience in hosting life science events, Global Engage is your ideal partner to either devise an agenda for you or work with you and your speakers to promote the online event to our extensive databases.